KYTX Kyverna Therapeutics, Inc.
Healthcare$8.61-0.69%ClosedMarket Cap: $377.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.68
P/S
0.00
EV/EBITDA
-2.29
DCF Value
$2.04
FCF Yield
-39.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-81.9%
ROA
-60.9%
ROIC
-71.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-41.4M | $-39.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-39.3M | $-37.8M | $— | — |
| FY null | $0.00 | NaN% | $-169.8M | $-161.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-38.7M | $-36.8M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-44.4M | $-42.1M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-47.4M | $-44.6M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-41.0M | $-37.5M | $— | — |
| FY null | $0.00 | -Infinity% | $-142.6M | $-127.5M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-38.8M | $-34.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-33.4M | $-28.8M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-29.4K | $-26.7K | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-21.4M | $-20.7M | $-0.48 | — |